OC
AXSM icon

Oppenheimer & Co’s Axsome Therapeutics AXSM Stock Holding History

Oppenheimer & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$993K Buy
+4,056
New +$880K 0.01% 934
2026
Q1 		– Sell
-7,076
Closed -$1.29M – 1692
2025
Q4 		$1.29M Buy
+7,076
New +$988K 0.02% 693

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Oppenheimer & Co's AXSM Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 4,056 shares worth $993K. The stake represents 0.01% of the portfolio and ranks #934 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in AXSM as recently as Q4 2025.

Oppenheimer & Co first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.29M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Oppenheimer & Co held 4,056 shares of Axsome Therapeutics worth $993K as of Q2 2026.
  • Axsome Therapeutics was a new Oppenheimer & Co position in Q2 2026.
  • Axsome Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #934 holding.
  • Oppenheimer & Co first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Oppenheimer & Co's Axsome Therapeutics position peaked at $1.29M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.